Hussein Ayad Ahmed, Halkes Constantijn M, Socié Gérard, Tichelli André, von dem Borne Peter A, Schaap Michel N P M, Foa Robin, Ganser Arnold, Dufour Carlo, Bacigalupo Andrea, Locasciulli Anna, Aljurf Mahmoud, Peters Christina, Robin Marie, van Biezen Anja A, Volin Liisa, De Witte Theo, Marsh Judith, Passweg Jakob R, Kröger Nicolas
Bone Marrow and Stem Cell Transplantation Program, King Hussein Cancer Center, Amman, Jordan.
BMT Centre Leiden, Leiden University Hospital, Leiden, The Netherlands.
Biol Blood Marrow Transplant. 2014 Sep;20(9):1448-50. doi: 10.1016/j.bbmt.2014.05.028. Epub 2014 Jun 6.
One hundred and forty patients who had undergone hematopoietic stem cell transplantation (HSCT) for myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) transformation after treatment of severe aplastic anemia (SAA) were identified in the European Group for Blood and Marrow Transplantation (EBMT) database. The median age at HSCT was 29 years (range, 1 to 66 years). The transplant donor was related in 49% cases and unrelated in 51% cases. The 5-year probability of relapse was 17%, and that of nonrelapse mortality was 41%. The 5-year overall survival was 45% ± 9%, better for patients untreated and patients in remission compared with patients with refractory disease. Our data indicate that allogeneic HSCT leads to prolonged survival in close to one-half of the patients transforming to MDS or AML from SAA.
在欧洲血液与骨髓移植组（EBMT）数据库中，确定了140例因严重再生障碍性贫血（SAA）治疗后发生骨髓增生异常综合征（MDS）或急性髓系白血病（AML）转化而接受造血干细胞移植（HSCT）的患者。HSCT时的中位年龄为29岁（范围1至66岁）。49%的病例移植供者为亲属，51%为非亲属。5年复发概率为17%，非复发死亡率为41%。5年总生存率为45%±9%，未治疗患者和缓解期患者的生存率优于难治性疾病患者。我们的数据表明，异基因HSCT可使近一半从SAA转化为MDS或AML的患者生存期延长。
